Acne Treatment Market Size, Share & COVID-19 Impact Analysis, By Product (Retinoids, Antibiotics, Isotretinoin, and Others), By Treatment Modality (Oral and Topical), By Age Group (10 to 17, 18 to 44, 45 to 64 and 65 Above) By Distribution Channel (Hospital pharmacies, Retail pharmacies and, E-pharmacies), and Regional Forecast, 2020-2027

The global acne treatment market size was valued at USD 5.46 billion in 2019 and is projected to reach USD 7.19 billion by 2027, exhibiting a CAGR of 4.6% during the forecast period.

Acne is a skin condition that arises when the hair follicles get plugged with dead skin cells and oil. Acne is most common among teenagers, though it affects people of all ages. The most common medication for acne is antibiotics, retinoids, and retinoid-like drugs. The growing rate of skin disorders is one of the major factors augmenting the demand for the market globally during the forecast period. For instance, in 2016, a study conducted by the University of Colorado found that, between 1990 and 2010, acne rates increased 11% among U.S. teenagers.

COVID 19 to Result in Reduction of Demand for Acne Treatment Products

The impact of the COVID-19 pandemic on the market is expected to reflect a decline in the growth rate across the analysis period. This is majorly due to the lockdown and social distancing rules enforced by the government to control the spread of the coronavirus led to a significant reduction in the number of patient visits/consultations with dermatologists. As acne treatment needs dermatologist’s consultation for medication and treatment, the market is estimated to witness a decline in its growth rate. A study conducted with dermatologists in the U.S. by the American Association of Dermatology reported almost a 43% decline in weekly patient consultations during the lockdown period as compared to the pre-COVID level. The drop in the number of dermatology-related consultations was considerably higher than specialties such as oncology due to the lack of urgency among patients and physicians to seek treatment for dermatological conditions. Many dermatologists contemplated closing down their practice due to the inability to stay afloat due to the significant decline in consultations. Moreover, various clinical studies for acne drugs have been postponed in 2020. The clinical development of the drug BTX 1204 for atopic dermatitis will remain suspended until further notice.

LATEST TRENDS

Request a Free sample to learn more about this report.

Growing Clinical Approval of Drugs for Acne Treatment to Drive the Market Growth

Increasing prevalence of the acne condition among teenagers and adults has caught the attention of the manufacturers, thereby boosting demand for acne medications. Drug development continues to focus on the challenge of treating acne effectively and safely. For instance, the U.S. Food and Drug Administration (FDA), has given a nod for the new abbreviated drug application for topical retinoid adapalene gel USP 0.3%, manufactured by Alembic Pharmaceuticals for treating acne vulgaris.

DRIVING FACTORS

Increasing Rates of Skin Conditions to Propel Market Growth

Rising prevalence of skin disorders will strongly propel acne treatment industry growth. There has been a significant rise in the number of dermatological services owing to the growing incidence of skin conditions such as inflammatory acne, eczema, and psoriasis. As per data from the American Association of Dermatology in 2018, around 50 million people in the U.S. suffer from acne. In Australia, more than 4% of the population or a million people are affected by the long term condition of the acne.

Launch of Novel Acne Products is Propelling Growth of the Market

The introduction of novel products are expected to have a huge impact on the acne treatment industry. For instance, in March 2020, COSMEDIX, a global trailblazer in skincare products announced the launch of Correct Rapid Relief Acne Treatment. Moreover, efficient product marketing to intrigue the target population is another significant factor in augmenting the market growth. For instance, in March 2020, following the launch of Acne Ultra Clear on Amazon UK, Derma Group have launched a new website for the brand.

RESTRAINING FACTORS

Side Effects Pertaining to Acne Products Will Limit Market Adoption

Despite, higher prevalence of chronic acne globally, certain factors are limiting the market growth. Among them is the side effect associated with acne products. The U.S. Food and Drug Administration (FDA) alerts the usage of certain over-the-counter (OTC) acne medications that can cause potentially life-threatening allergic reactions or severe irritation. For instance, in 2014, the FDA distributed certain safety alerts pertaining to the use of benzoyl peroxide for this treatment.

SEGMENTATION

By Product Analysis

To know how our report can help streamline your business, Speak to Analyst

Retinoid to Grow at a Faster Pace

On the basis of product, the market includes retinoids, antibiotics, isotretinoin, and others. The antibiotics segment held a dominant acne treatment market share in 2019. This is attributable to the growing approval of antibiotics for the treatment of acne, along with its high efficiency in exudate management of acne.

The retinoids segment is projected to register a higher CAGR by 2027 due to the increasing manufacturing of such products. For instance, in October 2019, Galderma received FDA Approval for AKLIEF (trifarotene) Cream, 0.005%, the first new retinoid molecule for the treatment of acne in over 20 years.

By Treatment Modality Analysis

Topical Segment Dominated the Market in 2019

Based on treatment modality, the market is segmented into topical and oral. The topical segment is estimated to dominate this market across the forecast timeframe. High growth is attributable to the increasing number of companies manufacturing topical solutions for treatment of acnes. This is due to the fact that the patient population suffering from acne conditions are primarily intrigued towards topical solutions as these products are easily available and are comfortable to use.

The oral segment is anticipated to project a significant CAGR during the forecast period owing to the increase in the prevalence of acne conditions coupled with the growing number of product launches.

By Age Group Analysis

18 to 44 Years Segment to Register a Higher CAGR

In terms of age group, the market is segmented into 10 to 17, 18 to 44, 45 to 64, and 65 above. The 18 to 44 years’ segment is expected to have a dominant share in the market during the forecast period. The dominance is due to an increase in the number of the patient population of this particular age group.

The 10 to 17 years’ segment is estimated to witness considerable growth across the forecast period owing to the increasing incidence of acne vulgaris amongst the mentioned teenage group. 

By Distribution Channel Analysis

E-pharmacies to Witness a Significant CAGR

The e-pharmacies segment is expected to witness a lucrative growth rate across the forecast period. This is due to the increasing number of online portals and websites commercializing acne products such as Walmart, Amazon, and several others. Moreover, growing demand for online delivery of products owing to COVID 19 pandemic will strongly suggest segmental expansion. The retail pharmacies segment is estimated to hold lion’s share owing to the increase in the number of OCT drugs approved for acne treatment across the globe. 

REGIONAL INSIGHTS

To get more information on the regional analysis of this market, Request a Free sample

The market size in North America stood at USD 3.28 billion in 2019. Dominance is attributable to the increasing prevalence of acne across the region. For instance, according to a study published by the American Association of Dermatology in 2018, around 50 million people in the U.S. are suffering from acne. The market in the Asia Pacific is expected to grow at a significant CAGR owing to rising awareness among the population about several treatments for acnes combined with the increasing number of companies entering the Asian market. Latin America & the Middle East & Africa accounted for a comparatively lower share of the regional market owing to the presence of a huge underpenetrated markets for acne treatment.

KEY INDUSTRY PLAYERS

Focus on Inorganic Growth Strategies Has Propelled Allergan, and Botanix Pharmaceuticals to Lead the Global Market.

The market is consolidated owing to the strong product portfolio and remarkable distribution network of major companies in developed and emerging countries. Currently, Allergan and Botanix lead the market, accounting for a dominant share in 2019. Other key players such as Galderma S.A., and others. 

LIST OF KEY COMPANIES PROFILED:

• Allergan (Dublin, Ireland)


• Botanix Pharmaceuticals (Northbridge, Australia)


• Galderma S.A. (Lausanne, Switzerland)


• Bausch Health Companies Inc (Bridgewater, U.S.) 


• GlaxoSmithKline Plc. (London, UK)


• Bayer AG (Leverkusen, Germany)


• Johnson & Johnson (New Jersey, U.S.)


• Pfizer Inc. (New York, U.S.)


• Other Players

KEY INDUSTRY DEVELOPMENTS:

• In June 2020 - Vyome Therapeutics Inc. announced the successful phase 2 trial result for its VB 1953; acne treatment solution.


• In June 2020 - Alembic Pharmaceuticals announced the approval from US health regulator for generic Adapalene gel used for treatment of acne.


• September 2019 – The Skincare Company announced the launch of a new line of revolutionary anti-acne products.

REPORT COVERAGE

An Infographic Representation of Acne Treatment Market

View Full Infographic

To get information on various segments, share your queries with us

The market research report provides a detailed analysis of the market and focuses on key aspects such as leading companies, product types, and leading applications of the product. Besides this, the report offers insights into the acne treatment market trends (Key trends) and highlights key industry trends and developments.

To gain extensive insights into the market, Request for Customization

Report Scope & Segmentation